Every question you ask can be matched with a suitable answer
Leave me a message
We take every suggestion of yours seriously
Wechat
Tan Xiaojun
·Senior reproductive medicine expert
·Postdoctoral fellow at Peking University
·PhD candidate at Xiangya School of Medicine, Central South
University
·Master’s tutor at Central South University
· Master's degree candidate in reproductive
medicine at the University of South China
· Professional training at Huazhong University
of Science and Technology and Tongji
Hospital Reproductive Center
Expertise:
diagnosis and treatment of infertility, first/second/third generation IVF (including
egg/sperm donation), microsperm retrieval, embryo freezing and resuscitation, artificial
insemination (including husband's sperm and sperm donation), paternity testing, chromosomal
disease
diagnosis, high-throughput gene sequencing, endometrial receptivity gene testing and other
clinical
technology applications. Many of these technologies are at the leading level both domestically
and
internationally.
Is it necessary to find hospital contact information to do third-generation test tubes overseas? Overseas third-generation test tubes, PGT-A,PGT-M, overseas test tube process, hospital contact information inquiry, genetic disease screening, cross-border assisted reproduction.
Is it necessary to find hospital contact information to do third-generation test tubes overseas? Look at the six premises before deciding whether to go abroad.
As soon as many people came up, they asked, "Can you give me the contact information of an overseas hospital? I want to make a third-generation test tube."
However, from the perspective of medical decision-making, "finding contact information first" is usually not the first step. It is the first step to confirm whether you really need to do the third generation test tube.
Make the concept clear first. The so-called "third generation test tube" in China essentially refers to preimplantation genetic testing (PGT). Common types include:
PGT-M, which is mainly used for the risk of known single-gene genetic diseases;
PGT-SR, mainly used for chromosome structure rearrangement;
PGT-A is mainly used to detect abnormal chromosome number in embryos. Both HFEA and ESHRE make a clear distinction between these types, which shows that the "third generation test tube" is not a single technology, let alone an "upgraded test tube" suitable for everyone.
Why are there more and more such demands? Because infertility itself is not uncommon. According to WHO, about one sixth of the adults in the world will experience infertility in their lifetime. For this reason, more and more people begin to pay attention to information such as cross-border assisted reproduction, overseas hospitals, genetic screening and success rate.
But to directly answer "Is it necessary to do it overseas", the conclusion is actually very clear:
For some people, it is necessary; For many people, it is unnecessary, or even just to change the problem from medical problems to information anxiety and decision-making costs.
There are usually several types of people who are suitable for giving priority to overseas third-generation test tubes.
The first category is that one or both husband and wife have a definite monogenic genetic disease carrier or family history, which is closer to the standard indication of PGT-M.
The second category is people with structural abnormalities such as balanced translocation and inversion of chromosomes, which may involve PGT-Sr.
In the third category, it is possible to further discuss whether PGT-A is needed only for people who have had repeated abortions, repeated embryo abnormalities, and repeated transplant failures and have passed the standardized evaluation.
The fourth category is people whose local laws and regulations, approval scope, accessible technology or scheduling can't meet their own needs, which is also the realistic motivation repeatedly mentioned by ASRM and ESHRE when discussing cross-border assisted reproduction.
A common misunderstanding must be pointed out here:
Many people interpret "overseas third-generation test tubes" as "more advanced, so it is more suitable for me". This premise is not rigorous. ASRM clearly pointed out in the Committee's opinion in 2024 that the value of PGT-A as a routine screening for all IVF patients has not been confirmed. HFEA also regards PGT-A as an additional treatment, not a standard procedure that all patients should use by default. In other words, if you don't do PGT-A, you will definitely be more pregnant; It's not that if you don't go abroad, you will definitely miss the opportunity.
What is the value of overseas medical treatment?
More often, the value is not in the word "overseas" itself, but in the following dimensions:
Is there a PGT project that matches your indications?
Whether blastocyst culture, biopsy, freezing and resuscitation are carried out stably in the laboratory;
Whether there is standardized genetic counseling;
Whether it can provide clear case evaluation, informed consent and follow-up;
Whether the local inspection can be connected with the overseas cycle.
ESHRE's documents on PGT and cross-border assisted reproduction emphasize that patients should focus on quality, safety, consultation, continuous care and transparent information when choosing centers, not just marketing language.
Let's talk about the process.
If you are really considering overseas third-generation test tubes, the reasonable order is usually not "adding hospital WeChat first", but these six steps:
First make a basic assessment, including the woman's age, ovarian reserve, previous pregnancy history, embryo situation, man's semen situation and genetic risk of both parties;
Then confirm whether you correspond to PGT-M, PGT-SR or PGT-A;
Then check whether the destination country or institution complies with the project;
Then look at the laboratory and genetic counseling configuration;
Then contact the hospital, see the cycle arrangement, quotation structure and stay time in the field;
Finally, it evaluates the connection between pregnancy protection, prenatal examination and legal documents after returning to China.
This is medical logic, not "who will go to which house as soon as he returns the news".
Many people will also ask: "Then I will get the contact information of the hospital first, so there is no harm, right?"
Yes, but the value is limited. Because the contact information can only solve the problem of "can you get in touch", it can't solve four more critical things:
First, are you fit to do it?
Second, whether you are doing the corresponding PGT type;
Third, whether the success rate given by the hospital is comparable;
Fourth, can you afford the hidden costs such as cross-border cycle interruption, review running back and forth, and language communication deviation?
HFEA clearly reminds that the success rate can only be used as a rough reference and cannot be used as a prediction of personal results; Numbers between different institutions cannot be mechanically compared horizontally.
There is another problem that is often overlooked:
Some people go overseas to make three generations of test tubes, not because they really need it, but because they want to improve efficiency at one time. Be more cautious at this time. Taking embryo transfer as an example, international supervision and guidelines have long emphasized that the risk of multiple births should be paid attention to, and single embryo transfer is more in line with the safety interests of mother and baby in many cases. The published data of HFEA also show that single embryo transfer is helpful to control the risk of multiple births at a low level. It shows that assisted reproduction is not "the more overlapping, the better", but "the more accurate the adaptation, the better".
Finally, a more direct judgment framework is given.
If you are just beginning to understand, have no clear history of genetic diseases, and have not systematically evaluated the causes of repeated failures, then what you need now is professional evaluation, not the contact information of overseas hospitals.
If you have clear genetic indications, limited local resources, and prepared for cross-border cycle costs and legal boundaries, then overseas third-generation test tubes can be one of the realistic options.
If you are only pushed by the words "overseas", "third generation" and "success rate", the high probability is not driven by medicine, but by information, and this kind of decision-making is more risky. This premise needs to be corrected first.
To sum up: whether it is necessary to find hospital contact information to do third-generation test tubes overseas does not depend on the contact information itself, but on whether you have clear indications, whether you understand the boundaries of PGT and whether you can complete the whole process management of cross-border treatment. Evaluate first, then contact; Look at the medical problems first, and then look at the channel problems.
Common aliases:Kyrgyzstan Tulip Reproductive Center, Tulip IVF, Tulip Reproductive Center, Tulip Hospital, Kyrgyz Tulip Reproductive Center, Kyrgyz Tulip Hospital
